Rekrutierung

Eingeschlossene Patienten: 23.180 (Stand 02. Dezember 2024)
Amgevita® (Adalimumab)	237
Benepali® (Etanercept)	1241
Cimzia® (Certolizumab)	1040
Enbrel® (Etanercept)	2874
Erelzi® (Etanercept)	572
Flixabi® (Infliximab)	10
Hukyndra® (Adalimumab)	9
Hulio® (Adalimumab)	262
Humira® (Adalimumab)	2910
Hyrimoz® (Adalimumab)	242
Idacio® (Adalimumab)	68
Imraldi® (Adalimumab)	233
Inflectra™ (Infliximab)	17
Jyseleca® (Filgotinib)	154
Kevzara® (Sarilumab)	223
Kineret® (Anakinra)	89
MabThera® (Rituximab)	1459
Nepexto® (Etanercept)	92
Olumiant® (Baricitinib)	547
Orencia® (Abatacept)	991
Remicade® (Infliximab)	762
Remsima® (Infliximab)	25
Rinvoq® (Upadacitinib)	312
Rixathon® (Rituximab)	20
RoActemra® (Tocilizumab)	1378
Ruxience® (Rituximab)	1
Simponi® (Golimumab)	475
Truxima® (Rituximab)	3
Tyenne® (Tocilizumab)	36
Xeljanz® (Tofacitinib)	397
Yuflyma® (Adalimumab)	48
Zessly® (Infliximab)	2
Kontrollen	6451